Luisa Accardi

Dr. Luisa Accardi

EVOR, Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1991 in Virology
Verified
Journal Article
Closed access
CGColomba Giorgi
Colomba Giorgi
LALuisa Accardi
Luisa Accardi
LNLoredana Nicoletti
Loredana Nicoletti
MGMaria Cristina Gro
Maria Cristina Gro
KTKazuaki Takehara
Kazuaki Takehara
DBDavid H.L. Bishop
David H.L. Bishop

1 February 2007 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
MBM. Branca
M. Branca
MCM. Ciotti
M. Ciotti
CGC. Giorgi
C. Giorgi
DSD. Santini
D. Santini
LBL. Di Bonito
L. Di Bonito
KSK. Syrjänen
K. Syrjänen

24 January 2019 in Cancers
Verified
Journal Article
Open access
PDF file
PBPaola Di Bonito
Paola Di Bonito
LALuisa Accardi
Luisa Accardi
LGLuisa Galati
Luisa Galati
Flavia FerrantelliFlavia Ferrantelli
Flavia Ferrantelli
Maurizio FedericoMaurizio Federico
Maurizio Federico
Some human papillomavirus (HPV) genotypes are universally recognized as major etiological agents not only of ano-genital tumors but also of head and neck cancers, which show increasing incidence. The evaluation of current and future therapeutic approaches against HPV-induced tumors is a global health priority, despite an effective prophylactic vaccine against 7 of the 12 genotypes involved in the etiology of tumors being currently available. In this review, we present the main anti-HPV therapeutic approaches in clinical experimentation, with a focus on a novel tumor antigen delivery method using engineered exosomes, that we recently developed. Our system allows the induction of an efficient unrestricted cytotoxic T lymphocyte (CTL) immune response against the HPV16-E7 tumor-associated antigen, with the formation of endogenously engineered exosomes, i.e., nanovesicles spontaneously released by all cell types. Immunogenic exosomes are uploaded with HPV16-E7 due to the fusion with a unique exosome-anchoring protein referred to as Nefmut. Intramuscular injection of a DNA vector expressing the fusion protein generates exosomes sufficiently immunogenic to elicit a potent anti-16E7 CTL immune response. The approach is described here and the advantages over other existing methodologies are reported.

1 February 1993 in Virus Research
Verified
Journal Article
Closed access
LALuisa Accardi
Luisa Accardi
MGMaria Cristina Grò
Maria Cristina Grò
PBPaola Di Bonito
Paola Di Bonito
CGColomba Giorgi
Colomba Giorgi

14 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GRGiuseppina La Rosa
Giuseppina La Rosa
MFMarta Fratini
Marta Fratini
LALuisa Accardi
Luisa Accardi
GDGraziana D'ORo
Graziana D'ORo
SLSimonetta Della Libera
Simonetta Della Libera
PBPaola Di Bonito
Paola Di Bonito
Epitheliotropic viruses can find their way into sewage. The aim of the present study was to investigate the occurrence, distribution, and genetic diversity of Human Papillomaviruses (HPVs) in urban wastewaters. Sewage samples were collected from treatment plants distributed throughout Italy. The DNA extracted from these samples was analyzed by PCR using five PV-specific sets of primers targeting the L1 (GP5/GP6, MY09/MY11, FAP59/64, SKF/SKR) and E1 regions (PM-A/PM-B), according to the protocols previously validated for the detection of mucosal and cutaneous HPV genotypes. PCR products underwent sequencing analysis and the sequences were aligned to reference genomes from the Papillomavirus Episteme database. Phylogenetic analysis was then performed to assess the genetic relationships among the different sequences and between the sequences of the samples and those of the prototype strains. A broad spectrum of sequences related to mucosal and cutaneous HPV types was detected in 81% of the sewage samples analyzed. Surprisingly, sequences related to the anogenital HPV6 and 11 were detected in 19% of the samples, and sequences related to the “high risk” oncogenic HPV16 were identified in two samples. Sequences related to HPV9, HPV20, HPV25, HPV76, HPV80, HPV104, HPV110, HPV111, HPV120 and HPV145 beta Papillomaviruses were detected in 76% of the samples. In addition, similarity searches and phylogenetic analysis of some sequences suggest that they could belong to putative new genotypes of the beta genus. In this study, for the first time, the presence of HPV viruses strongly related to human cancer is reported in sewage samples. Our data increases the knowledge of HPV genomic diversity and suggests that virological analysis of urban sewage can provide key information useful in supporting epidemiological studies.

4 January 2006 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
MBM Branca
M Branca
CGC Giorgi
C Giorgi
DSD Santini
D Santini
PBPaola Di Bonito
Paola Di Bonito
MCM Ciotti
M Ciotti
KSK Syrjänen
K Syrjänen
Aims: Increased angiogenesis leads to invasion in cervical cancer. Vascular endothelial growth factors (VEGFs) are involved in angiogenesis, but molecular links to the most important aetiological agent, human papillomavirus (HPV), need clarifying. Material/Methods: Archival samples—150 squamous cell carcinomas (SCCs) and 152 cervical intraepithelial neoplasia (CIN) lesions—were examined immunohistochemically for anti-VEGF-C antibody and for HPV by polymerase chain reaction (PCR). Follow up data were available for all SCC cases, and 67 CIN lesions were monitored with serial PCR to assess HPV clearance/persistence after treatment. Results: High risk (HR) HPV types were closely associated with CIN (odds ratio, 19.12; 95% confidence interval, 2.31 to 157.81) and SCC (27.25; 3.28 to 226.09). There was a linear increase of VEGF-C expression—weak in CIN1 and intense in CIN3 and SCC (20.49; 8.69 to 48.26). VEGF-C upregulation was a sensitive (93.5%; 95% CI, 90.1% to 96.9%) marker of HR-HPV type (4.70; 2.17 to 10.21), but lost its significance in multivariate regression—p16 INK4a and survivin were equally strong independent predictors of HR-HPV. Aberrant expression of VEGF-C did not predict clearance/persistence of HR-HPV after treatment of CIN. In cervical cancer, VEGF-C had no prognostic value in univariate or multivariate survival analysis. After adjustment for HR-HPV, FIGO stage, age, and tumour grade, only FIGO stage and age remained independent prognostic predictors. Conclusions: VEGF-C is an early marker of cervical carcinogenesis, with linearly increasing expression starting from low grade CIN. VEGF-C expression is closely related to HR-HPV in cervical lesions, probably because of its p53 independent upregulation by the E6 oncoprotein of HR-HPV.